Clinigen Raises $80 Mil. In Rare U.K. Flotation While Europe's Wellington Partners Raises $91 Mil. For New Life Sciences Fund
This article was originally published in The Pink Sheet Daily
Hopes in Europe’s cash-strapped biotech sector were rekindled when specialty drug and contract services company Clinigen said it will be Britain’s first public pharma listing in five years and by investors from Europe, the U.S. and the Middle East piling into a new life sciences investment fund set up by pan-European VC firm Wellington Partners.